Heart Failure

A look into the role of heart failure treatment in health care and the overall provision of optimal medical therapy.

A subgroup analysis from DAPA-HF show the SGLT2 inhibitor provided efficacy regardless of HFrEF patient gender.

Investigators determined that acid-base disturbances like lactate clearance influenced C diff infection after cardiac surgery.

Researchers compare the NYHA class identifier with KCCQ-QS.

The Harmony Transcatheter Pulmonary Valve System is designed to treat adult and pediatric patients with pulmonary valve regurgitation.

The role of early aggressive treatment in preventing progression of heart failures and the importance of understanding the root cause of disease.

Javed Butler, MD, MPH, MBA, discusses the staging and difficulties associated with diagnosing heart failure.

Stimulating steroid receptor co-activators may play a role in repairing heart tissue following severe myocardial infarction.

The majority of previous studies have focused on this link in the male population.

Researchers test 3 different machine learning models to aid in expanding the number of variables needed to better predict outcomes.

A longtime clinician writes on the signs and risks of fatal heart attack events, including the Widowmaker.

Unhealthy lifestyles during the pandemic may increase the risk of cardiovascular disease.

Researchers find a significant benefit at day 28 when compared to a group taking a placebo.

The approval was based on data from the PARAGON-HF study.

Dr. Khan discusses some of the risk factors associated with CHD.

Researchers believe identifying more risk factors could be beneficial in reducing cardiovascular disease.

Two experts offer perspectives on the importance and state of cardiovascular health in women.

The approval is the first indication for a new pathway of care—one which has been linked to reduced heart failure death and hospitalization.

The SOLOIST-WHF trial indicates that SGLT2 inhibition may lead to an overall reduction in cardiovascular-related deaths and hospitalizations.

The agency is expected to rule on the Novartis treatment in 2021.

2020 was the year when regulators, clinicians, and patients had no choice but to embrace the concept of wearable monitoring devices. But it’s been a long time coming for the technology class.

The LIVMOR Halo AF Detection System has received 510(k) clearance from the US FDA and becomes the first prescriptible wearable for continuous heart monitoring in patients with atrial fibrillation.

The investigators also found the effects of dapagliflozin were similar in patients with type 2 diabetes and those without type 2 diabetes.

Cytokinetics announces presentations on two trials assessing omecamtiv mecarbil in patients with heart failure and reduced ejection fraction.

This edition from the 10 Year Plan features perspective from leadership at ACC and ESC, as well as survey results from cardiologists.